CN1616002A - Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis - Google Patents
Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis Download PDFInfo
- Publication number
- CN1616002A CN1616002A CN 200410073075 CN200410073075A CN1616002A CN 1616002 A CN1616002 A CN 1616002A CN 200410073075 CN200410073075 CN 200410073075 CN 200410073075 A CN200410073075 A CN 200410073075A CN 1616002 A CN1616002 A CN 1616002A
- Authority
- CN
- China
- Prior art keywords
- medicine
- present
- group
- parts
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 243
- 201000007100 Pharyngitis Diseases 0.000 title claims abstract description 35
- 206010001093 acute tonsillitis Diseases 0.000 title claims abstract description 35
- 208000016150 acute pharyngitis Diseases 0.000 title claims abstract description 33
- 239000007937 lozenge Substances 0.000 title claims abstract description 9
- 241001164374 Calyx Species 0.000 claims abstract description 30
- 239000002994 raw material Substances 0.000 claims description 49
- 238000002360 preparation method Methods 0.000 claims description 39
- 241000628997 Flos Species 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 15
- 241000207929 Scutellaria Species 0.000 claims description 9
- 241001530126 Scrophularia Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 2
- 241001106044 Physalis Species 0.000 claims 4
- 206010011224 Cough Diseases 0.000 abstract description 48
- 208000002193 Pain Diseases 0.000 abstract description 34
- 230000036407 pain Effects 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 10
- 206010037660 Pyrexia Diseases 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract description 2
- 241000596154 Belamcanda Species 0.000 abstract 1
- 241000050051 Chelone glabra Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract 1
- 241000293861 Scrophularia nodosa Species 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 75
- 238000012360 testing method Methods 0.000 description 62
- 229940079593 drug Drugs 0.000 description 54
- 241000699670 Mus sp. Species 0.000 description 47
- 238000005516 engineering process Methods 0.000 description 37
- 230000008961 swelling Effects 0.000 description 29
- 239000003826 tablet Substances 0.000 description 26
- 244000064622 Physalis edulis Species 0.000 description 25
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 230000000844 anti-bacterial effect Effects 0.000 description 22
- 230000037396 body weight Effects 0.000 description 22
- 230000003203 everyday effect Effects 0.000 description 17
- 239000009916 yin-huang Substances 0.000 description 17
- 239000002671 adjuvant Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 241000700199 Cavia porcellus Species 0.000 description 13
- 208000000114 Pain Threshold Diseases 0.000 description 13
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 13
- 230000037040 pain threshold Effects 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 102000002322 Egg Proteins Human genes 0.000 description 12
- 108010000912 Egg Proteins Proteins 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 230000000954 anitussive effect Effects 0.000 description 12
- 230000036760 body temperature Effects 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 239000008187 granular material Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000006188 syrup Substances 0.000 description 12
- 235000020357 syrup Nutrition 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000002683 foot Anatomy 0.000 description 11
- 230000002496 gastric effect Effects 0.000 description 11
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 11
- 210000004681 ovum Anatomy 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000001802 infusion Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 229940013618 stevioside Drugs 0.000 description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 10
- 235000019202 steviosides Nutrition 0.000 description 10
- 229960004793 sucrose Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 8
- 241000194017 Streptococcus Species 0.000 description 8
- 241000193998 Streptococcus pneumoniae Species 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 230000004856 capillary permeability Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 235000014347 soups Nutrition 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 7
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000037386 Typhoid Diseases 0.000 description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 description 7
- 230000036592 analgesia Effects 0.000 description 7
- 229940124584 antitussives Drugs 0.000 description 7
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000002949 hemolytic effect Effects 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 231100000668 minimum lethal dose Toxicity 0.000 description 7
- 210000003800 pharynx Anatomy 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 201000008297 typhoid fever Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 239000002510 pyrogen Substances 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 230000009747 swallowing Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000588747 Klebsiella pneumoniae Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000009849 deactivation Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229960005181 morphine Drugs 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 229960002800 prednisolone acetate Drugs 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 241000219109 Citrullus Species 0.000 description 4
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241000235070 Saccharomyces Species 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 208000038016 acute inflammation Diseases 0.000 description 4
- 230000006022 acute inflammation Effects 0.000 description 4
- 239000006189 buccal tablet Substances 0.000 description 4
- 229960004415 codeine phosphate Drugs 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000005069 ears Anatomy 0.000 description 4
- 210000003026 hypopharynx Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 238000005057 refrigeration Methods 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 240000006409 Acacia auriculiformis Species 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940095686 granule product Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000002741 palatine tonsil Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229940095262 codeine phosphate 30 mg Drugs 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 125000002324 prednisone group Chemical group 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 210000002396 uvula Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 244000152526 Agathosma crenulata Species 0.000 description 1
- 235000013388 Agathosma crenulata Nutrition 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 235000009269 Barosma crenulata Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010030094 Odynophagia Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000035109 Pneumococcal Infections Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000004676 abdominal muscle contraction Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 201000010550 acute laryngitis Diseases 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003616 anti-epidemic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 241001609914 bacterium 150 Species 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940062650 buchu Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical group C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229940102542 prednisone 5 mg Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000009792 yinqiao Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410073075 CN1284573C (en) | 2004-09-14 | 2004-09-14 | Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410073075 CN1284573C (en) | 2004-09-14 | 2004-09-14 | Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1616002A true CN1616002A (en) | 2005-05-18 |
CN1284573C CN1284573C (en) | 2006-11-15 |
Family
ID=34765249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410073075 Expired - Lifetime CN1284573C (en) | 2004-09-14 | 2004-09-14 | Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1284573C (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292779C (en) * | 2005-09-22 | 2007-01-03 | 太阳石(唐山)药业有限公司 | Chinese traditional medicine preparation for treating paediatric acute tonsillitis |
CN104524150A (en) * | 2015-01-22 | 2015-04-22 | 李海红 | Traditional Chinese medicine for treating amygdalitis |
CN105168375A (en) * | 2015-09-15 | 2015-12-23 | 中国科学院西北高原生物研究所 | Application of slender-fruited hypecoum extract in preparation of antibacterial medicines |
CN112494598A (en) * | 2020-12-23 | 2021-03-16 | 烟台新时代健康产业有限公司 | Effective part composition for treating pharyngitis and application thereof |
-
2004
- 2004-09-14 CN CN 200410073075 patent/CN1284573C/en not_active Expired - Lifetime
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292779C (en) * | 2005-09-22 | 2007-01-03 | 太阳石(唐山)药业有限公司 | Chinese traditional medicine preparation for treating paediatric acute tonsillitis |
CN104524150A (en) * | 2015-01-22 | 2015-04-22 | 李海红 | Traditional Chinese medicine for treating amygdalitis |
CN105168375A (en) * | 2015-09-15 | 2015-12-23 | 中国科学院西北高原生物研究所 | Application of slender-fruited hypecoum extract in preparation of antibacterial medicines |
CN105168375B (en) * | 2015-09-15 | 2019-01-08 | 中国科学院西北高原生物研究所 | Application of the thinfruit hypecoum herb extract in preparation antibacterials |
CN112494598A (en) * | 2020-12-23 | 2021-03-16 | 烟台新时代健康产业有限公司 | Effective part composition for treating pharyngitis and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1284573C (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1856568A (en) | Fermentation and culture method, fermented plant extract, fermented plant extract powder and composition containing the fermented plant extract | |
CN1899333A (en) | Bupleurum root extract, its preparing method and its use | |
CN1212856C (en) | Medicine composition for treating sphagitis and preparing method thereof | |
CN1876099A (en) | Cough-stopping granule with honeysuckle flower and bulbus fritilariae | |
CN1284573C (en) | Oral administration or lozenge medicine for treating acute pharyngitis and acute tonsillitis | |
CN1739677A (en) | Houjiling prepn for treating throat diseases and its use | |
CN1879688A (en) | Preparation for treating wind-heat type cold, its preparation process and quality control method | |
CN1290553C (en) | Pharmaceutical composition for treating menorrhagia and method for preparing the same | |
CN1947747A (en) | Traditional Chinese medicine composition contg. luteolin and capsule of sweeping forsythia and its prepn. method and use | |
CN1323689C (en) | Medicine for treating prostatic accrementition and its preparation | |
CN1579531A (en) | Medicinal composition for treating anemopyretic cold and its preparation method | |
CN101053566A (en) | Acetylcysteine or its salt and anti-infectious medicine composition | |
CN1868502A (en) | Medicine composition used for treating rheumatoid arthritis, and its prepn. method | |
CN101032544A (en) | Medicine composition of compound honeysuckle organic acid and the preparing method of the agent thereof | |
CN1554407A (en) | Medicine for clearing away lung-heat, eliminating phaegn, reliveing cough and asthma and its preparing method | |
CN1579455A (en) | Composition of traditional Chinese medicine for large intestine hygropyretic disease and its preparation method | |
CN1517326A (en) | Capejasmine cycloolefines ether terpene extract and its preparation method and use | |
CN1954870A (en) | Medical composite prepared by sarcandra and oldenlandia | |
CN1947742A (en) | Medicine composition contg. radix bupleuri and Radix scutellariae glucoside, prepn. method and use thereof | |
CN1911307A (en) | Medicine for treating postoperative gastroenteropathy | |
CN1616003A (en) | Medicine for treating prostatitis | |
CN1513510A (en) | Chinese medicine compound preparation for treating acute pharyngolaryngitis and its preparation method | |
CN1287835C (en) | Pharmaceutical composition for treating coronary heart disease and angina pectoris and its preparing process | |
CN1947735A (en) | Medicine composition contg. isatis root and scutellariae glucoside | |
CN1181872C (en) | Medicine for acute pulmonary infection and its preparing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090213 Address after: 1028, North Ring Road, Yin Hu Road, Shenzhen, zip code: 518029 Co-patentee after: Xi'an Shang Yikang Institute of Medicine Patentee after: 39 medical Limited by Share Ltd Address before: Room 2004, B, fish garden, No. 158, Yanta West Road, Shaanxi, Xi'an 710061, China Patentee before: Ma Yaoru |
|
ASS | Succession or assignment of patent right |
Owner name: SANJIU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: MA YAORU Effective date: 20090213 |
|
DD01 | Delivery of document by public notice |
Addressee: Ma Penggang Document name: Notification that Application Deemed not to be Proposed |
|
C56 | Change in the name or address of the patentee |
Owner name: CHINA RESOURCES SANJIU MEDICAL + PHARMACEUTICAL CO Free format text: FORMER NAME: SANJIU PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 1028 No. 518029 Shenzhen Yinhu North Road intersection Co-patentee after: Xi'an Shang Yikang Institute of Medicine Patentee after: China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Address before: 1028 No. 518029 Shenzhen Yinhu North Road intersection Co-patentee before: Xi'an Shang Yikang Institute of Medicine Patentee before: Sanjiu Pharmaceutical Co., Ltd. |